[vc_row][vc_column][vc_column_text]The $47 million TTRA initiative, supported by the Medical Research Future Fund (MRFF), is providing a new integrated research program to improve the prevention, management and treatment of diabetes and cardiovascular disease (D&CVD) in Australia. Research efforts will focus on the most pressing areas of unmet clinical and research needs in D&CVD, which are leading causes of death and disability in Australia.
The TTRA program is designed to support and incentivise translation as a natural course of activity for those applying and receiving funding.
MTPConnect is pleased to announce partnerships with ANDHealth, Medical Device Partnering Program (MDPP) and UniQuest to provide advice and mentoring for funding recipients.
MTPConnect Managing Director & CEO, Dr Dan Grant, has welcomed the TTRA partners, citing their credentials as preeminent organisations specialising in translation and commercialisation of digital health, medical technology, medical devices, biotechnology and pharmaceuticals.
“We are delighted to announce our partnerships with ANDHealth, MDPP and UniQuest for the TTRA as we embark on a mission to improve the prevention, diagnosis, treatment and management of diabetes and cardiovascular disease in Australia,” Dr Grant said.
“Our experience leading a number of Medical Research Future Fund programs has proven the value of building in a component for guidance and support for research applicants,” he said.
UniQuest is Australia’s leading technology transfer company, whose innovation portfolio includes Australia’s first blockbuster vaccine Gardasil®. UniQuest’s Executive Director of Commercialisation, Dr Mark Ashton says bringing commercialisation experience to early stage research will transform ideas to impact.
”We are looking forward to drawing on the industry expertise of our team at the Queensland Emory Drug Discovery Initiative (QEDDI) and our 35 years’ experience in commercialisation to support applicants in the translation of their research, with the view to improving the outlook for patients with diabetes and cardiovascular disease around the world,” Dr Ashton said.
MDPP Executive Director, Professor Karen Reynolds leads the ideas incubator to support the development of novel medical devices and assistive technologies.
“MDPP is honoured to once again partner with MTPConnect and support the development of novel preventive, diagnostic and therapeutic approaches and products to improve outcomes for diabetes and cardiovascular disease. With the rapid changes within the community, health and business environments, the TTRA will provide a strategic and coordinated effort to translate cutting-edge research to knowledge for two disease states that affect millions of Australians each year,” Professor Karen Reynolds said.[/vc_column_text][/vc_column][/vc_row]